| Code | CSB-RA004847MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to DT-7012, designed for research targeting C-C chemokine receptor type 8 (CCR8). CCR8 is a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper 2 (Th2) cell subsets, where it mediates chemotactic responses to ligands CCL1 and CCL18. This receptor plays a critical role in immune regulation and tissue homeostasis, with particular importance in the tumor microenvironment where CCR8-positive Tregs contribute to immunosuppression and tumor immune evasion. Elevated CCR8 expression has been associated with various malignancies including colorectal cancer, breast cancer, and hepatocellular carcinoma, making it an attractive target for cancer immunotherapy research.
DT-7012 is a preclinical or early clinical research-stage monoclonal antibody targeting CCR8. Its Fc segment has been optimized to significantly enhance its antibody-dependent cell-mediated cytotoxicity (ADCC) effect for CCR8-positive Tregs. This biosimilar provides researchers with a reliable tool for exploring CCR8-mediated immune mechanisms, evaluating Treg depletion strategies, and studying chemokine receptor signaling pathways in various disease models. It supports investigations into immune checkpoint modulation and combination immunotherapy approaches.
There are currently no reviews for this product.